Boston Scientific (NYSE:BSX) Stock Sold Off by Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $50,001 and $100,000 in Boston Scientific stock on September 4th. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Boston Scientific Stock Up 0.4%

Shares of BSX opened at $44.10 on Tuesday. The business’s fifty day moving average price is $46.97 and its two-hundred day moving average price is $52.24. The firm has a market capitalization of $63.92 billion, a price-to-earnings ratio of 17.86, a PEG ratio of 1.05 and a beta of 0.57. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $105.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts predict that Boston Scientific Corporation will post 3.27 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Robert W. Baird set a $56.00 price target on Boston Scientific in a research note on Thursday, July 30th. Canaccord Genuity Group lowered their target price on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Leerink Partners set a $60.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. UBS Group decreased their price target on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $60.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Twenty-three equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $70.19.

Institutional Trading of Boston Scientific

A number of large investors have recently bought and sold shares of the business. QRG Capital Management Inc. lifted its stake in Boston Scientific by 129.4% in the second quarter. QRG Capital Management Inc. now owns 375,620 shares of the medical equipment provider’s stock valued at $16,031,000 after buying an additional 211,855 shares in the last quarter. Andra AP fonden increased its position in shares of Boston Scientific by 13.9% during the second quarter. Andra AP fonden now owns 193,622 shares of the medical equipment provider’s stock worth $8,264,000 after acquiring an additional 23,694 shares in the last quarter. SkyView Investment Advisors LLC acquired a new stake in shares of Boston Scientific during the second quarter worth $107,000. Bullseye Investment Management LLC acquired a new stake in shares of Boston Scientific during the second quarter worth $41,000. Finally, Rench Wealth Management Inc. lifted its position in Boston Scientific by 27.5% in the 2nd quarter. Rench Wealth Management Inc. now owns 27,952 shares of the medical equipment provider’s stock valued at $1,193,000 after acquiring an additional 6,033 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Edward Ludwig purchased 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Michael Mahoney bought 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders purchased 194,522 shares of company stock valued at $9,385,210. Company insiders own 0.34% of the company’s stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.